Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ME-344

Known as: mTOR1/2 Kinase Inhibitor ME-344 
An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ME-344 is a second generation isoflavone with unusual cytotoxic properties that is in clinical testing in cancer. To identify… Expand
2019
2019
Purpose: We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
SummaryBackground This multicenter, open-label, phase Ib study was designed to assess the safety, pharmacokinetics and… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
2016
2016
ME-344 [(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol] is a second-generation derivative natural product… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
The isoflavone ME-344 is a potent anti-cancer agent with preclinical and clinical efficacy in solid tumors. Yet, the mechanism of… Expand
Review
2016
Review
2016
Recent evidence highlights that energy requirements of cancer cells vary greatly from normal cells and they exhibit different… Expand
2015
2015
Isoflavonoids have been shown to inhibit tumor proliferation and metastasis by activating cell death pathways. As such, they have… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2015
2015
The current phase 1, open‐label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic… Expand
2013
2013
Background: ME-344 is a second generation isoflavone-derived drug candidate that causes caspase-independent cell death in… Expand
2013
2013
Background: Epithelial ovarian cancer (EOC) is the most lethal of all gynecologic malignancies. Despite initial responsiveness to… Expand
  • figure 2
  • figure 3